References
- Drummond M F. Economic analysis alongside clinical trials: problems and potential. J Rheumatol 1995; 22: 1403–7
- Drummond M F, O'Brien B J. Economic analysis alongside clinical trials: practical considerations. J Rheumatol 1995; 22: 1418–9
- Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chon Dis 1967; 20: 637–48
- Croog S H, Levine S, Testa M A, Brown B, Bulpitt C J, Jenkins C D, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64
- Freemantle N, Drummond M F. Should clinical trials with concurrent economic analyses be blinded. JAMA 1996; 277: 63–4
- Nord E. Background paper for the OECD Directorate for Education, Employment, Labour and Social Affairs. A review of synthetic health indicators. OECD, Paris 1997
- Drummond M F, Davies L M. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Techno/Assess Health Care 1991; 7: 561–73
- Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada2nd edn. CCOHTA, Ottawa 1997
- Burnand B, Kerman W N, Feinstein A R. Indexes and boundaries for ‘quantitative significance’ in statistical decisions. J Clin Epidemiol 1990; 43: 1273–84
- Roset M, Badia X, Mayo N E. Sample size calculations in studies using the EuroQoL-SD. Qual Life Res 1999; 8: 539–49
- Drummond M F, O'Brien B J, Stoddart G L, Torrance G W. Methods for the economic evaluation of healthcare programmes. Oxford University Press, Oxford 1997
- Translating functional health and wellbeing: International Quality of Life Assessment (IQOLA) project studies of the SF-36 Health Survey. J Clin Epidemiol 1998; 51(Special Issue, Nov.), Gandek B Ware J E, eds.
- Johnson J A, Ohinmaa A, Murti B, Sintonen H, Coons S J. Comparison of Finnish and US-based visual analog scale valuations of the EQ-SD measure. Med Decis Making 2000; 20: 281–9
- Le Gales C, Buron, Costel C. N, Rosman S, Slama G. The French Health Utilities Index Mark 3 (Abstract). Value in Health 2000; 3: 103